|
|
|
|
Direct Cost |
Indirect Cost |
|
1K22AI136593-01A1 |
Innate Lymphoid Cell Loss in HIV-1 and SIV Infection |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$150,000 |
$8,357 |
$158,357 |
1R01AI149119-01A1 |
Immunotherapy of KPC Infection |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$320,014 |
$166,407 |
$486,421 |
1R01AI155156-01A1 |
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$509,885 |
$280,995 |
$790,880 |
1R21AI150413-01 |
Reservoir modulation by Nef and anti-nef CTL |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$150,000 |
$105,000 |
$255,000 |
1R21AI157434-01 |
Persistence of SARS-CoV-2 in Wastewater |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$305,302 |
$110,790 |
$416,092 |
1R56AI143937-01A1 |
Mechanisms of dmLT Adjuvant |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$171,813 |
$88,913 |
$260,726 |
272201300004I-0-759302000001-1 |
SVEU - Core Activities - Administrative and Technical Support |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$78,125 |
272201300004I-P00005-27200006-1 |
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$602,145 |
272201300004I-P00005-27200007-1 |
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$67,942 |
272201300004I-P00008-27200003-1 |
Efficacy of DNA and Protein Co-Immunization Protocol to Protect Macaques from SHIV Infection |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$36,871 |
272201700022C-P00004-9999-1 |
NONHUMAN PRIMATE (NHP) CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH DEVELOPMENT |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$1,800,685 |
272201700033I-0-759302000001-1 |
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$6,749,208 |
272201700033I-0-759302000002-1 |
Task B10: Evaluation of vaccines against VEEV and EEEV aerosol exposure in cynomolgus macaques |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
|
|
$1,283,493 |
4R33AI136100-03 |
Genetically Modified Gamma Delta T Cells to Target SIV Reservoirs |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$299,232 |
$209,462 |
$508,694 |
5F30AI150452-03 |
Modifying CMV-specificT cells with a novel bicistronic CD4-CAR/maC46 vector to target HIV |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$50,520 |
|
$50,520 |
5R01AI080581-10 |
Immune signaling molecules involved in promoting the pathogenesis of eosinophilic esophagitis (EoE) |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$300,000 |
$155,125 |
$455,125 |
5R01AI120033-06 |
Improved Therapeutics and Diagnostics for PneumocystisPneumonia |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$311,945 |
$136,340 |
$448,285 |
5R01AI125542-04 |
The Role of STa in ETEC Pathogenesis |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$250,000 |
$126,250 |
$376,250 |
5R01AI131433-04 |
Testing novel microbicide candidates in sustained release formulations |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$433,953 |
$219,796 |
$653,749 |
5R01AI132223-04 |
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail |
TULANE UNIVERSITY OF LOUISIANA |
NIAID |
$975,088 |
$133,442 |
$1,108,530 |